· Investment Strategies · 1 source · Updated · Verified
Basecamp Research Raises $140M Series C for AI-Designed Cell Therapies
Basecamp Research closed a $140 million Series C led by S32 to move its biological foundation models toward preclinical cell-therapy programs.
By Venture Capital Tracker Editorial
Funding event
Basecamp Research
Led by S32
Basecamp Research closed a $140 million oversubscribed Series C on September 23, 2026. S32 led the round. Nvidia, the NATO Innovation Fund, Anthropic's Anthology Fund, Catalio, Redalpine, Singular, True Ventures and other investors participated.
Deal terms
| Field | Detail |
|---|---|
| Company | Basecamp Research |
| Financing | $140M Series C |
| Lead | S32 |
| Selected participants | Nvidia; NATO Innovation Fund; Anthology Fund; Catalio; Redalpine; Singular; True Ventures |
| Valuation | Not disclosed |
| Status | Company announced |
Why this financing matters
Basecamp is trying to differentiate its biological models with proprietary data gathered through global biodiversity partnerships. The Series C is intended to move that data-and-model platform into AI-designed therapeutic programs, including in-vivo cell therapies.
The investor group combines AI infrastructure, defence-linked innovation capital and specialist life-sciences funds. That mix reflects the breadth of the platform story, but the next proof points will come from biology rather than model benchmarks.
The clinical reality
The programs remain preclinical. Basecamp did not disclose human-trial timelines, revenue, partnership economics or a valuation. Any claims about model quality or therapeutic performance should remain attributed to the company until validated through published studies and clinical results.
Bottom line
The confirmed event is a $140 million Series C. It gives Basecamp the capital to translate a biological foundation-model thesis into drug programs, where timelines, safety and efficacy will determine whether the data advantage is real.
Follow Venture Capital Tracker on Google
Add VCT as a preferred source to see more of our venture-capital reporting in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
